Scienture Holdings (SCNX) Corporate presentation summary

Strategic vision and mission

• Focused on developing and commercializing innovative specialty pharmaceuticals to address unmet clinical and market needs, aiming to improve patient outcomes and expand shareholder value.

• Utilizes proprietary technology platforms and agile commercialization models to accelerate product launches and maximize market reach.

• Emphasizes data-driven insights, reducing patient friction, and strong channel partnerships to ensure effective delivery of therapies.

Leadership and expertise

• Executive team and board bring decades of experience in pharmaceutical development, commercialization, and strategic consulting, with involvement in several blockbuster drugs.

• Leadership includes expertise in R&D, commercial launches, economics, and pharmaceutical distribution.

Product portfolio and pipeline

• Commercialized Arbli™, the first FDA-approved liquid losartan for hypertension, and Rezenopy®, a high-dose naloxone nasal spray for opioid overdose.

• Pipeline includes SCN-104 (migraine injection pen), SCN-106 (CV biosimilar), and SCN-107 (extended-release pain injection), with anticipated launches and filings through 2030.

• Products target CNS, cardiovascular, and pain management markets, leveraging differentiated formulations and delivery systems.